4/18/2013

Impel Neuropharma's nose-to-brain drug delivery method sent a small peptide molecule into the brain in a seven-patient trial, the company's chief scientist said. The technology could have applications in central nervous system disorders and pain relief. Angel investors, the NIH, the Pentagon and Washington state's Life Sciences Discovery Fund provided support for the project.

Full Story:
Xconomy

Related Summaries